These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 29855342)

  • 1. Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why.
    Derenzini E; Rossi A; Treré D
    J Hematol Oncol; 2018 May; 11(1):75. PubMed ID: 29855342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate.
    Scala F; Brighenti E; Govoni M; Imbrogno E; Fornari F; Treré D; Montanaro L; Derenzini M
    Oncogene; 2016 Feb; 35(8):977-89. PubMed ID: 25961931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting ribosome biogenesis as a novel therapeutic approach to overcome EMT-related chemoresistance in breast cancer.
    Ban Y; Zou Y; Liu Y; Lee S; Bednarczyk RB; Sheng J; Cao Y; Wong STC; Gao D
    Elife; 2024 Sep; 12():. PubMed ID: 39259576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
    J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility?
    Brighenti E; Treré D; Derenzini M
    Oncotarget; 2015 Nov; 6(36):38617-27. PubMed ID: 26415219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis.
    Bursac S; Brdovcak MC; Donati G; Volarevic S
    Biochim Biophys Acta; 2014 Jun; 1842(6):817-30. PubMed ID: 24514102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways.
    Lindström MS; Bartek J; Maya-Mendoza A
    Cell Death Differ; 2022 May; 29(5):972-982. PubMed ID: 35444234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer.
    Bursać S; Prodan Y; Pullen N; Bartek J; Volarević S
    Trends Cancer; 2021 Jan; 7(1):57-76. PubMed ID: 32948502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribosome biogenesis and control of cell proliferation: p53 is not alone.
    Donati G; Montanaro L; Derenzini M
    Cancer Res; 2012 Apr; 72(7):1602-7. PubMed ID: 22282659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ribosome Biogenesis-Cancer Connection.
    Penzo M; Montanaro L; Treré D; Derenzini M
    Cells; 2019 Jan; 8(1):. PubMed ID: 30650663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guarding the 'translation apparatus': defective ribosome biogenesis and the p53 signaling pathway.
    Chakraborty A; Uechi T; Kenmochi N
    Wiley Interdiscip Rev RNA; 2011; 2(4):507-22. PubMed ID: 21957040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cancer via ribosome biogenesis: the cachexia perspective.
    Figueiredo VC; McCarthy JJ
    Cell Mol Life Sci; 2021 Aug; 78(15):5775-5787. PubMed ID: 34196731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 activation during ribosome biogenesis regulates normal erythroid differentiation.
    Le Goff S; Boussaid I; Floquet C; Raimbault A; Hatin I; Andrieu-Soler C; Salma M; Leduc M; Gautier EF; Guyot B; d'Allard D; Montel-Lehry N; Ducamp S; Houvert A; Guillonneau F; Giraudier S; Cramer-Bordé E; Morlé F; Diaz JJ; Hermine O; Taylor N; Kinet S; Verdier F; Padua RA; Mohandas N; Gleizes PE; Soler E; Mayeux P; Fontenay M
    Blood; 2021 Jan; 137(1):89-102. PubMed ID: 32818241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribosome biogenesis: An emerging druggable pathway for cancer therapeutics.
    Catez F; Dalla Venezia N; Marcel V; Zorbas C; Lafontaine DLJ; Diaz JJ
    Biochem Pharmacol; 2019 Jan; 159():74-81. PubMed ID: 30468711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acrolein preferentially damages nucleolus eliciting ribosomal stress and apoptosis in human cancer cells.
    Wang HT; Chen TY; Weng CW; Yang CH; Tang MS
    Oncotarget; 2016 Dec; 7(49):80450-80464. PubMed ID: 27741518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.
    Kusnadi EP; Trigos AS; Cullinane C; Goode DL; Larsson O; Devlin JR; Chan KT; De Souza DP; McConville MJ; McArthur GA; Thomas G; Sanij E; Poortinga G; Hannan RD; Hannan KM; Kang J; Pearson RB
    EMBO J; 2020 Nov; 39(21):e105111. PubMed ID: 32945574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of the 5S RNP-Mdm2-p53 ribosomal stress pathway delays the initiation but fails to eradicate established murine acute myeloid leukemia.
    Jaako P; Ugale A; Wahlestedt M; Velasco-Hernandez T; Cammenga J; Lindström MS; Bryder D
    Leukemia; 2017 Jan; 31(1):213-221. PubMed ID: 27256803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIM1 destabilization activates a p53-dependent response to ribosomal stress in cancer cells.
    Sagar V; Caldarola S; Aria V; Monteleone V; Fuoco C; Gargioli C; Cannata S; Loreni F
    Oncotarget; 2016 Apr; 7(17):23837-49. PubMed ID: 26993775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells.
    Cai X; Gao L; Teng L; Ge J; Oo ZM; Kumar AR; Gilliland DG; Mason PJ; Tan K; Speck NA
    Cell Stem Cell; 2015 Aug; 17(2):165-77. PubMed ID: 26165925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth control and ribosomopathies.
    Teng T; Thomas G; Mercer CA
    Curr Opin Genet Dev; 2013 Feb; 23(1):63-71. PubMed ID: 23490481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.